Skip to content Skip to sidebar Skip to footer
Subscribe Now
Exclusive_Jonathan Benjamin_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor Shots: The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
October 22, 20210Comments

Read more

Viewpoints_Rich Birhanzel
VIEWPOINTS

PharmaShots Interview: Accenture’s Rich Birhanzel Shares Insight on the Investment in ixlayer

In an interview with PharmaShots, Rich Birhanzel, Senior Managing Director & Global Health Lead at Accenture shared his views on the investment in ixlayer to provide health solutions for diagnostic testing Shots: The company has made a strategic investment in ixlayer through Accenture Ventures to expand access to virtual diagnostic health testing. The company's telehealth platform allows players across the healthcare ecosystem…
October 22, 20210Comments

Read more

Viewpoints_Anish Suri
VIEWPOINTS

PharmaShots Interview: Cue Biopharma’s Anish Suri Shares Insights on the Data of CUE-401 Presented at 2021 FOCIS Annual Meeting

In an interview with PharmaShots, Anish Suri, Ph.D., President, and Chief Scientific Officer at Cue Biopharma shared his views on new preclinical data of CUE-401 for the treatment of autoimmune diseases at the 2021 FOCIS Annual Meeting Shots: The company has reported the preclinical data of CUE-401 which can induce & expand regulatory T cells in vitro and in vivo & has the potential to…
October 15, 20210Comments

Read more

Viewpoints_Brandon Smith
VIEWPOINTS

PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition of Prothena and Novo Nordisk

In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk's acquisition of Prothena's ATTR amyloidosis program includes PRX004 Shots: The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena's PRX004 and broader ATTR amyloidosis program Novo Nordisk acquires Prothena's subsidiary and gets WW rights to the IP and…
October 15, 20210Comments

Read more

Viewpoints_Suela Sulo
VIEWPOINTS

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care

In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how this study will shift the way to approach nutrition across the continuum of care. Shots: A study published in the Journal of Primary Care and Community Health has shown that a new…
October 13, 20210Comments

Read more

Viewpoints_Dr. Pierre Pellier
VIEWPOINTS

PharmaShots Interview: CTMA-Dr. Pierre Pellier Shares Insight on CT-SCOUT to Detect Patients for Clinical Trials in IBD

In an interview with PharmaShots, Dr. Pierre Pellier, CEO of CTMA, share his views on CT-SCOUT that helps to boost patient recruitment in the clinical trials for IBD Shots: CTMA developed the web mobile platform, CT-Scout to boost patient recruitment in the clinical trials by facilitating a quick and simple study detection for eligible patients CT-Scout is currently available in…
October 11, 20210Comments

Read more

Viewpoints_Dr. Barbara Klencke
VIEWPOINTS

PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153

In an interview with PharmaShots, Dr. Barbara Klencke, MD, Chief Medical Officer at Sierra Oncology share her views on the license agreement for AZD5153 with AstraZeneca to treat myelofibrosis Shots: AstraZeneca signs an exclusive license agreement with Sierra for AZD5153 to expand myelofibrosis pipeline. The agreement will provide a novel compound into Sierra's pipeline to supply therapies for rare cancers Sierra plans…
October 11, 20210Comments

Read more

Viewpoints_Salom Juethner
VIEWPOINTS

PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro

In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal Allergy Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…
October 6, 20210Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]